Ipratropium Bromide: Progress in API Synthesis Process Development
Classification: Industry News
Publication:2026-02-03 11:10
I. Overview
Iptacopan is currently the only orally administered small-molecule inhibitor of complement factor B (CFB) approved worldwide, and it is also the first targeted therapy approved for adult patients with complement 3 glomerulopathy (C3G) and adult primary immunoglobulin A nephropathy (IgAN). Additionally, it has been approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Figure 1. Structure of Ipratropium bromide
1.1 Information on the Market Launch of Ipratropium Bromide
In the early 2010s, Novartis identified Factor B of the complement alternative pathway as a central regulatory protein of the C3 convertase; inhibition of this factor simultaneously blocks both C3 activation and the formation of the membrane attack complex, thereby modulating excessive activation of the complement system. Through high-throughput screening and structural optimization, Novartis developed the lead compound LNP023 (ipragliflozin).
From 2017 to 2023, a series of clinical trials were conducted for iprocapan, which in 2019 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). In 2020, it further obtained FDA Breakthrough Therapy Designation for its indications, paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G).
On December 5, 2023, eplacimen was approved by the FDA for the treatment of PNH, and subsequently received approval in 2024 and 2025, respectively, for the treatment of C3G and IgAN.

Figure 2. Marketing Information for Ipratropium Bromide
1.2 Patent Landscape of Ipratropium Bromide in Major Countries and Regions

Table 1: Patent Status of Ipratropium Compounds in Major Countries and Regions

Table 1: Patent Status of Ipratropium Bromide Polymorphs in Major Countries and Regions
II. Retrosynthetic Analysis of the Ipratropium Bromide API Molecule
According to retrosynthetic analysis, ipracitine (compound 1) consists of two key fragments, 2 and 3, and contains two chiral centers; the efficient synthesis of compound 2 represents the technical core of ipracitine preparation. The following section will focus on the synthetic route to compound 2, with a brief summary of the synthetic route to compound 3.

Figure 3. Retrosynthetic analysis of iprophan (Compound 1)
III. Synthetic Route for Key Intermediate 2 of Ipratropium Bromide
3.1 Chemical Method
Route 1 (patent CN105579444B, original research company) [1]: Starting from 4-bromobenzonitrile and 4-methoxypyridine, the target intermediate 2 is obtained through a ten-step sequence of reactions, including Grignard reagent exchange–addition, hydrogenation, carbonyl reduction, separation of cis–trans isomers, removal of the TBDPS group, resolution, etherification, nitrile hydrolysis, esterification, and deprotection of the Cbz group.

Figure 4. Synthetic route of intermediate 2, pathway one
Route Two [2] : Starting from (2R,4S)-1-Boc-4-hydroxypyridine-2-carboxylic acid, intermediate 2 is obtained via a three-step sequence involving etherification, decarboxylative cross-coupling, and Boc deprotection.

Figure 5. Synthetic Route II for Intermediate 2
3.2 Chemical–Enzymatic Method
Route Three (Original Research Company’s Patent CN112513025B) [3] : Using methyl 4-iodobenzoate and 4-methoxypyridine as starting materials, the target intermediate 2 was obtained through a six-step sequence involving Grignard reagent exchange–addition, reduction, ketoreductase catalysis, TBS protection, etherification, and hydrogenation.

Figure 6. Synthetic route three for intermediate 2
Route 4 (patent CN112513025B owned by the original research company) [3]: Starting from 4-methoxypyridine, an intermediate 2 is obtained through a six-step sequence—reduction followed by deprotection, asymmetric coupling, ketoreductase catalysis, TBS protection, etherification, and deprotection—or compound 28 can be directly converted into 14 via etherification, subsequently yielding intermediate 2. [4] 。

Figure 7. Synthetic route for intermediate 2, variant four
Shangke Bio (Patent CN202511577063.8) has also developed a method for preparing intermediate 2 via ketoreductase catalysis, achieving a substrate concentration of up to 120 g/L, a conversion rate of 99.3%, and an enantiomeric excess (ee) of 100%.
IV. Synthetic Route for Intermediate 3 of Ipratropium Bromide
Route 1 (Patent CN105579444B, original research company) [1]: Starting from 5-methoxy-7-methyl-1H-indole, the intermediate 3 is obtained via a two-step reaction sequence (Boc protection followed by formylation).

Figure 8. Synthetic route for intermediate 3, variant 1
Route 2 (patent CN112513025B, original research company) [3]: Starting from 3,5-dimethyl-4-nitrophenol, the intermediate 3 is obtained through a six-step sequence involving benzylation, cyclization, Boc protection, debenzylation, formylation, and etherification.
Route 3 (patent CN112513025B owned by the original research company) [3]: Starting from 7-methylindole, the intermediate 3 is obtained through a four-step sequence involving oxidation, Boc protection, formylation, and etherification.
Route 4 (patent CN104603127B owned by the original research company) [5]: Starting from 7-methylindole, an intermediate 3 is obtained through a seven-step sequence involving oxidation, allylation, Claisen rearrangement, etherification, Boc protection, olefin transfer, and oxidation.

Figure 9. Synthetic routes II, III, and IV for intermediate 3
V. Synthesis of Ipratropium Bromide
Route One [6] : The original research company reported that compounds 2 and 3 were converted into iproclopram by reductive amination followed by hydrolysis.

Figure 10. Synthetic route of ipropanthine I
Route Two [7] Another study reported a synthetic route to ipracitine that bypasses the pre‑formation of intermediate 2, using 2,3‑dihydropyridine‑4(1H)-one and compound 3 as starting materials. Through a six‑step sequence—aldol condensation, asymmetric addition, asymmetric reduction, ethylation, hydrolysis, and Boc deprotection—the target compound ipracitine was obtained.

Figure 11. Synthetic route II of iprophan.
VI. Other Drug Information Targeting CFB

Table 3: Information on CFB-Targeted Drugs in Clinical or Marketing Application Stages
References
[1] Christopher Michael Adams, Michael Paul Capparelli, Takeru Ehara, et al. Piperidinyl indole derivatives and their use as complement factor B inhibitors: China, 105579444B[P]. 2018-05-01.
[2] Rajender Nallagonda, Rachel Quan, Lauren Grant, et al. Unveiling the Stereoselectivity Aspects of Metallaphotoredox Decarboxylative Arylation[J]. ACS Catalysis, 2024, 14(17), 13439-13450.
[3] Peng Fu, Yu Gai, Feng Gao, et al. Chemical method for preparing phenylpiperidinylindole derivatives: China 112513025B [P]. 2025-03-25.
[4] Zhiwei Tang, Shaojie Chu, Xuesong Wu, et al. A Practical Method for Synthesizing Iptacopan[J].Molecules, 2024, 29(10), 2289.
[5] Christopher Michael Adams, Charles Babu, Michael Paul Capparelli, et al. Complement pathway modulators and their applications: China 104603127B[P]. 2016-10-05.
[6] Anna Schubarta, Karen Andersonb, Nello Mainolfi, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases[J]. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116(16), 7926-7931.
[7] Liu Zhiping, Huang Dong, Li Qiuling. A method for preparing IPTACOPAN: China 118063431A [P]. 2024-05-24.
Leave a Message Online
Shanghai Public Security Bureau Internet Information Service Security Filing No. 31011502015262